Terrie Curran, Phathom Pharmaceuticals CEO (Arcutis)
Phathom Pharmaceuticals resubmits NDA for acid blocker, bags $130M+ from offering
Phathom Pharmaceuticals is making another run at getting a green light to add two new indications for its drug vonoprazan while …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
